There is no widely available cure for HIV. A handful of people have been cured through extreme medical procedures, and antiretroviral therapy (ART) can control the virus so effectively that a person living with HIV can expect to live nearly as long as someone without it. But eliminating the virus entirely from the body remains one of the hardest problems in medicine. Here’s why, and where things stand.
Why HIV Is So Hard to Cure
HIV attacks immune cells called CD4 T cells. Most of the time, the virus hijacks these cells, forces them to produce copies of itself, and destroys them in the process. But some infected CD4 cells slip into a resting, or latent, state. In this quiet phase, the cells don’t produce any new virus. That means the immune system can’t detect them, and antiretroviral drugs, which work by interrupting viral replication, have no effect on them either.
These dormant infected cells form what researchers call the latent reservoir. They can hide for years in lymph nodes, the central nervous system, the genital tract, and other tissues throughout the body. If a person stops taking ART, virus stored in the reservoir reactivates and viral levels rebound, often within weeks. The reservoir is the core obstacle to a cure: you can suppress HIV indefinitely, but you can’t easily find and destroy every last hiding cell.
The Few People Who Have Been Cured
A small number of individuals, often referred to by the cities where they were treated (the Berlin Patient, the London Patient, the Düsseldorf Patient, and a few others), have been cured of HIV. All of them had life-threatening blood cancers that required stem cell transplants. In each case, the donor cells carried a rare genetic mutation called CCR5-delta32, which blocks the doorway HIV uses to enter CD4 cells. After the transplant, the donor’s resistant cells gradually replaced the recipient’s vulnerable ones, leaving the virus with nowhere to go. It disappeared.
These cases prove a cure is biologically possible, but they aren’t a practical model for the roughly 39 million people living with HIV worldwide. Stem cell transplants are dangerous, requiring intensive chemotherapy to wipe out the existing immune system first. They carry significant risks of organ damage, infection, and death. Doctors only recommend them when someone already needs one to survive cancer.
What “Cure” Means in HIV Research
Scientists distinguish between two goals. A sterilizing cure would completely eliminate every trace of HIV from the body. A functional cure would keep the virus suppressed below detectable levels without the need for daily medication, even though small amounts of HIV might still remain. Most current research is focused on the functional cure, since destroying every last reservoir cell may not be necessary if the immune system can be trained to keep the virus permanently in check.
Strategies Scientists Are Testing
Shock and Kill
This approach tries to flush HIV out of hiding. Drugs called latency-reversing agents “shock” dormant infected cells into waking up and producing viral proteins again. Once those cells reveal themselves, the immune system or additional drugs can target and destroy them. The concept is straightforward, but in practice the shock has been too weak to activate enough reservoir cells, and the kill step hasn’t reliably finished the job. Multiple clinical trials are ongoing to find more potent combinations.
Gene Editing
Inspired by the CCR5-delta32 mutation that cured the transplant patients, researchers are using gene-editing tools to try to replicate that protection without a transplant. One approach, called EBT-101, uses CRISPR technology delivered through an intravenous infusion to cut HIV’s genetic material directly out of infected cells. It entered a Phase 1 clinical trial, the earliest stage of human testing, to evaluate safety. Results have not yet been published. The technology is promising in concept but still years from proving whether it works at scale.
Broadly Neutralizing Antibodies
These are lab-engineered antibodies that can recognize and neutralize a wide range of HIV strains. In clinical trials at Rockefeller University, participants who received a single infusion of two broadly neutralizing antibodies instead of daily ART were 91 percent less likely to experience viral rebound over 20 weeks compared to a placebo group. Half of participants still had undetectable virus at 48 weeks, and one in three remained undetectable at 72 weeks, roughly a year to a year and a half after their last treatment. That’s not a cure, but it suggests the immune system can be given tools to hold HIV at bay for extended periods without pills.
Therapeutic Vaccines
Unlike preventive vaccines (which have so far eluded researchers for HIV), therapeutic vaccines aim to train the immune system of someone already living with HIV to control the virus on its own. Dozens of candidates are in Phase 1 trials, including vaccines built on mRNA technology similar to the platform used for COVID-19 vaccines. All are in early stages, and none has yet demonstrated the ability to replace ART.
What Treatment Can Do Right Now
While a cure remains out of reach, modern ART has transformed HIV from a fatal diagnosis into a manageable chronic condition. Daily medication suppresses the virus to undetectable levels in the blood. According to the CDC, a person with an undetectable viral load has zero risk of transmitting HIV to sexual partners, a principle known as Undetectable = Untransmittable, or U=U.
Life expectancy has improved dramatically. A large collaborative study published in The Lancet HIV found that a 40-year-old man who started ART after 2015 could expect to live an additional 37 years, compared to about 41 years for the average man in the general population. For women, the gap was similarly narrow: 39 additional years on ART versus nearly 46 in the general population. People who started treatment with strong immune systems (high CD4 cell counts) had life expectancies only a few years shorter than their HIV-negative peers. Starting treatment early and staying on it consistently closes the gap further.
ART does require lifelong adherence. Missing doses allows the virus to rebound from its reservoirs, potentially leading to drug resistance. Newer long-acting options, including injections given every one to two months, are making adherence easier for some people, but the fundamental requirement remains: without a cure, treatment never stops.
How Close Is a Cure?
No cure strategy is close to being available to the general public. The most advanced approaches, including broadly neutralizing antibodies and shock-and-kill combinations, are still in clinical trials, and even optimistic timelines put a scalable cure years away. Gene editing is further behind. The latent reservoir remains a formidable barrier because it is tiny, scattered across the body, and invisible to the immune system.
What has changed is that researchers now have multiple plausible paths forward rather than none. The rare cured patients proved the virus can be eliminated. Broadly neutralizing antibodies showed that long stretches of viral control without daily pills are achievable. Gene editing offers a way to replicate the genetic resistance that made those transplant cures work. None of these threads has reached the finish line, but all are advancing through human trials simultaneously, which is a meaningful shift from even a decade ago.